| Literature DB >> 34725041 |
Hanchao Cheng1, Yuou Zhang1, Jing Sun2, Yuanli Liu1.
Abstract
OBJECTIVE: To quantify the overall and dynamic effects of the implementation of the zero-mark-up medicines policy on the proportionate revenue generated from medicines, medical services and government subsidies at Chinese tertiary public hospitals.Entities:
Keywords: health economics; health policy; health services research; health systems; hospital-based study
Mesh:
Year: 2021 PMID: 34725041 PMCID: PMC8562510 DOI: 10.1136/bmjgh-2021-007089
Source DB: PubMed Journal: BMJ Glob Health ISSN: 2059-7908
Figure 1Stepwise implementation of the policy and median proportionate revenues of 136 sample hospitals (2012–2020).
Overall effect of the zero-mark-up medicines policy (2012–2020)
| Model | Measurement | Observations (n) | Coefficient | Cluster-robust SE | P value |
| Pooled regression model (model 1) | Proportionate medicines revenue | 1210 | −0.0916 | 0.0058 | <0.001 |
| Proportionate medical service revenue | 1210 | 0.0886 | 0.0064 | <0.001 | |
| Proportionate government subsidy revenue | 1210 | 0.0030 | 0.0040 | 0.452 | |
| Hospital-level fixed-effect model (model 2) | Proportionate medicines revenue | 1210 | −0.0912 | 0.0057 | <0.001 |
| Proportionate medical service revenue | 1210 | 0.0879 | 0.0063 | <0.001 | |
| Proportionate government subsidy revenue | 1210 | 0.0033 | 0.0039 | 0.398 | |
| Two-way fixed-effect model (model 3) | Proportionate medicines revenue | 1210 | −0.0323 | 0.0086 | <0.001 |
| Proportionate medical service revenue | 1210 | 0.0348 | 0.0098 | 0.001 | |
| Proportionate government subsidy revenue | 1210 | −0.0025 | 0.0076 | 0.740 |
Dynamic effect of the zero-mark-up medicines policy (2012–2020)
| Length of policy implementation | Observations (n) | Marginal effect on the proportionate medicines revenue | Marginal effect on the proportionate medical service revenue | Marginal effect on the proportionate government subsidy revenue |
| The year of implementation | 1210 | −0.0776 (0.0148)*** | 0.0862 (0.0167)*** | −0.0086 (0.0116) |
| 1 year after implementation | 1210 | −0.1065 (0.0134)*** | 0.1077 (0.0151)*** | −0.0012 (0.0118) |
| 2 years after implementation | 1210 | −0.1304 (0.0124)*** | 0.1087 (0.0136)*** | 0.0216 (0.0104)* |
| 3 years after implementation | 1210 | −0.1329 (0.0108)*** | 0.1126 (0.0119)*** | 0.0203 (0.0089)* |
| 4 years after implementation | 324 | −0.1415 (0.0118)*** | 0.1266 (0.0135)*** | 0.0149 (0.0096) |
| 5 years after implementation | 162 | −0.1694 (0.0125)*** | 0.1170 (0.0213)*** | 0.0524 (0.0229)* |
| 6 years after implementation | 27 | −0.1843 (0.0151)*** | 0.1529 (0.0219)*** | 0.0314 (0.0143)* |
*P<0.05, ***P<0.001.
Cluster-robust SEs are within parentheses.
Figure 2Dynamic effect of the zero-mark-up medicines policy (2012–2020).